Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact.
about
MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agentsIdentification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptorHwanggeumchal sorghum induces cell cycle arrest, and suppresses tumor growth and metastasis through Jak2/STAT pathways in breast cancer xenograftsRole of ubiquitination in IGF-1 receptor signaling and degradation.Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulationMdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor.The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK⁺ T-cell lymphomaRole of insulin-like growth factor 1 receptor signalling in cancer.Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia.Molecular characterization of pediatric gastrointestinal stromal tumors.Insulin-like growth factor-I receptor is suppressed through transcriptional repression and mRNA destabilization by a novel energy restriction-mimetic agent.Determination of cellular uptake and intracellular levels of Cenersen (Aezea(®), EL625), a p53 antisense oligonucleotide in acute myeloid leukemia cells.Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma.Functional antagonism of β-arrestin isoforms balance IGF-1R expression and signalling with distinct cancer-related biological outcomes.Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation.Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment.Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients.
P2860
Q24297439-F08B5C71-ED28-4F31-A611-783E2E4D0F5BQ24306866-D0DE4C0B-C505-4AFF-99AE-3AE6AAE3344EQ27334603-F03E4F5D-0154-4B0A-AE8E-1610A578D945Q33280993-A2E37A96-17F0-42E4-8DF8-0946B1144204Q34387886-C95AB013-398E-4708-AC42-C0FD85A40CF1Q35167761-8CDD6DCE-E9DD-45FF-AC11-F6524D5FAB83Q35556180-B28315F5-0D7F-4D58-8E62-398CB0B8773EQ36163571-990CBADF-D900-428E-B8E3-AADBE1239E6DQ37158722-140A110F-27EE-4A07-B46D-30EAC42E0223Q37247100-F8AEA461-6B8E-4CCA-B4E4-4C84036D58B9Q37354557-FFDF0889-9807-4036-8CEE-5ED218BFD0AEQ39286137-D3B73168-2109-4312-AEA8-019BCD72692EQ42119362-5AA6C3D0-E781-4791-BF49-9962C33E3809Q42619195-F962FF0A-FA00-4218-981C-4F87FF4CB6E0Q45305367-5D0EBEBC-2CF5-441C-8E07-7306CCD36E61Q47113667-49057DC0-1F39-453F-BD31-7136E60911C5Q55352057-1E02C938-8D89-4503-95A4-6008BCF036A6Q55518473-C90D11F9-FBFA-4100-BB84-9194425FD0AD
P2860
Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Increased expression of insuli ...... errant p53: functional impact.
@en
type
label
Increased expression of insuli ...... errant p53: functional impact.
@en
prefLabel
Increased expression of insuli ...... errant p53: functional impact.
@en
P2093
P4510
P1433
P1476
Increased expression of insuli ...... berrant p53: functional impact
@en
P2093
Lundeberg J
P304
P407
P577
2000-09-01T00:00:00Z